Genzyme, Ilex deal

GENZ said its planned acquisition of ILXO is now expected to close in the fourth quarter, instead of around mid-year as previously expected. GENZ said the delay reflects discussions with the Federal Trade Commission (FTC) regarding "outstanding issues regarding a proposed consent decree" for certain solid organ transplant applications of ILXO's cancer drug Campath alemtuzumab. ...